Accuray (NASDAQ:ARAY - Get Free Report) is anticipated to announce its Q3 2025 earnings results after the market closes on Wednesday, April 30th. Analysts expect Accuray to post earnings of ($0.05) per share and revenue of $101.53 million for the quarter. Accuray has set its FY 2025 guidance at EPS.
Accuray (NASDAQ:ARAY - Get Free Report) last issued its earnings results on Wednesday, February 5th. The medical equipment provider reported $0.02 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.01) by $0.03. Accuray had a negative net margin of 0.96% and a negative return on equity of 9.75%. On average, analysts expect Accuray to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Accuray Stock Up 0.3 %
NASDAQ:ARAY traded up $0.01 during midday trading on Monday, hitting $1.59. 118,698 shares of the company were exchanged, compared to its average volume of 725,078. Accuray has a fifty-two week low of $1.40 and a fifty-two week high of $2.95. The company has a market capitalization of $162.99 million, a PE ratio of -31.70 and a beta of 1.30. The company has a current ratio of 1.62, a quick ratio of 0.88 and a debt-to-equity ratio of 3.51. The company has a fifty day simple moving average of $1.76 and a 200 day simple moving average of $1.94.
Wall Street Analysts Forecast Growth
Separately, StockNews.com raised Accuray from a "hold" rating to a "buy" rating in a research report on Friday, April 11th.
Check Out Our Latest Stock Report on ARAY
About Accuray
(
Get Free Report)
Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.
Read More
Before you consider Accuray, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Accuray wasn't on the list.
While Accuray currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
